Objectives. To present a step by step approach for the diagnosis of adrenal incidentaloma (AI).
INTRODUCTION
Definition. Adrenal tumours that are discovered "incidentally" during radiology for reasons exclusive of endocrine related symptoms or work up for cancer staging and are larger than 1cm, are called adrenal incidentalomas (AI) [1] [2] [3] [4] [5] [6] [7] [8] .
History. Initially it was used the term "incidental adrenal mass" or the term "suprarenal mass". The term "incidentaloma" was coined by professors G. W. Geelhoed and E. M. Druy [8] (personal communication). The term originates from the word "incidental", which according to "Webster's Third New International Dictionary" is "something that is incidental: a subordinate or incidental item" [9] . In 1989 Professor Linos DA suggested the term Adrenaloma [7] . Farrugia F.A. et al., in 2016 [10] proposed the term "Epinephroma" which originates from the Greek word Epinephridion. Epinephridion originates from the Greek words Epi (Επί = upon [11] ) and Nephros (Νεφρός = Kidney [11] ) meaning that it is something that it is upon the Kidney. AI is a radiological term.
Etiology. AI are benign or malignant, functioning or non functioning and originate from the cortex or the medulla or they are metastatic [5] . Upon discovery of an AI three questions should be answered. First, is it hormone producing or not, second, is it malignant or benign and if malignant, is it primary or secondary?
Incidence. The incidence of AI varies between 4% to 5% of all the abdominal CT and MRI [12] [13] [14] [15] . Even though there is no difference between sex or race the incidence of AI increases as the age increases [16] [17] [18] [19] .
THE NEW EUROPEAN'S SOCIETY OF ENDO-CRINOLOGY, CLINICAL PRACTICE GUIDE-LINES ON THE MANAGEMENT OF ADRENAL INCIDENTALOMAS [NEGMAI]:
In August, 2016, the European Society of Endocrinology in collaboration with the European Network for the Study of Adrenal Tumors published their recommendations on the management of adrenal incidentalomas [5] . Their guidelines were graded according to the "GRADE" system [Grading of Recommendations Assessment, Development and Evaluation]. They graded 20 of the recommendations/suggestions. Of them 17 were classified as "very low" and three as "low". There were no "moderate" or "strong" recommendations/suggestions. They replaced the term "subclinical Cushing's syndrome" (SCS) with a new term that they coined, the term "autonomous cortisol secretion" which applies.
They use this term for patients who do not have any sign or symptom of Cushing's syndrome but who, after overnight 1 mg dexamethasone (DST) their serum cortisol level is higher than 138 nmol/L (higher than 5 µg/dL). Surprisingly the NEGMAI do not recommend any testing of ACTH levels, so it seems very odd that they characterize it as "autonomous".
The SCS is much more prevalent than Cushing's syndrome. The prevalence of SCS is between 5-30% of AI cases and up to 4-7% of the adult population. So, the SCS prevalence is roughly 0.2-2.0% in general population [20] [21] [22] !
We are going to further comment on these new guidelines in the various steps below.
STEP 1: (Radiology) IF AI DISCOVERED BY ULTRASOUNDS OR CT SCAN:
AI is a radiological term, so the first who discovers and starts examining it is the radiologist. Radiological and biochemical studies are done in parallel and are described in STEPS 1 and 2. We shall describe first the radiological part of the studies and then the biochemical tests. If AI is bilateral we follow the same steps as if it was unilateral [5] .
NEGMAI [5] recommend multidisciplinary approach in cases that we are not sure that the lesion is benign, there are symptoms and signs of hormone over production, in cases that the imaging modality showed growth over time and in cases when we consider surgery.
The majority of AI are discovered by either ultrasound or CT scan [23] [24] [25] . If AI was discovered by ultrasound then proceed with a CT scan. If AI was discovered by CT scan then proceed examining the following characteristics of CT scan: the radiation attenuation coefficient (density, which is expressed in Hounsfield units (HU)), the imaging characteristics of the tumour and the size of the tumour.
The NEGMAI suggest that if the noncontrast CT is consistent, with what they refer as, "a benign adrenal mass" that is; (HU≤10), smaller than 4cm and homogeneous, there is no need for further radiology [5] . Contrary to this, in a study done by Song J. H. et al. [26] , where they concluded that homogeneous density, can be seen in both benign and malignant lesions. After the intravenous administration of iodinated contrast medium, cancer lesions due to their vascularity enhance avidly. If there was no necrosis the tumor density may be homogeneous [27] [28] [29] [30] .
If AI is of a low density (<10 HU), that means that the lipid fraction of the tumour is high, which is characteristic of lipid-rich mild adenomas [6] . Attenuation values of <10 HU on an unenhanced CT are practically diagnostic for adenomas [27] . Sometimes, though, pheochromocytomas may have density less than 10 HU. If HU is as low as -30 to -100 we diagnose myelolipoma [6] . Myelolipomas and cysts are heterogeneous [12, 23] .
Approximately 30% of adenomas are lipid poor adenomas and they are characterized by high initial density (usually up to 20 HU and in some cases up to 30 HU) [6] . In that case, density should be assessed before and 1 minute after the administration of i.v. contrast enhancement, followed by acquisition (washout phase) 10 or 15 minutes later. An absolute washout coefficient that is greater than 50% after 10 minutes, 60% after 15 minutes and a relative washout coefficient that is greater than 40% indicates a mild character (benign) of the lesion [6, 27, 31, 32] . If washout <50% then there is a non adenoma lesion [33] .
In NEGMAI, in a flowchart on the management of patients with adrenal incidentalomas (page G14) in case "of potentially malignant" recommend washout CT as the third option after FDG-PET and MRI. We do not agree with this. We believe that if CT was done without "washout" technique we should proceed with "washout CT" since it gives better results than MRI [12, 14] . In various studies it was shown that if CT it is not helpful in determining the nature of an AI the MRI cannot confer more information [34] .
When an adrenal mass has malignant morphologic features, such as an irregular margin and heterogeneous density with a thick enhancing rim, at presenting contrast-enhanced CT, it likely represents a malignant lesion. Morphologic features that can be seen in both benign and malignant tumours are smooth margins and homogeneous density [26] .
Pheochromocytomas have density similar to muscle tissue, that is, approximately 30-40 HU [37] . Sometimes the pheochromocytoma may present with density less than 10 HU and also more than 60% washout [38] .
If size is more than 4cm the majority of authors will consider surgical excision [5, 30, 39, 40] . We cannot rely on size to predict malignancy.
Even from the majority of lesions ≥4 cm, the majority [84%] are benign and lesions less than 4 cm may be malignant [13] .
The available data suggest that nearly all lesions smaller than 4 cm are benign [41] . The size of the majority of AI remains stable, 5-25% increases and 3-4% decreases [41] . Any increase in size should be regarded as malignant until proved otherwise [42] . If the size remains stable it implies benignity [28, 43] . It is extremely rare for a malignant tumour to remain stable after 6 months of followup imaging [28, 42, 43] .
IF AI DISCOVERED BY MRI:
An MRI evaluation of the adrenals should usually consist of both T1 and T2 weighted images [44, 45] . Dynamic serial T1 images obtained after intravenous administration of Gd-DTPA are used to show enhancement patterns of adrenal masses [6] .
MRI also makes use of the lipid content of adenomas. In-phase and out-of-phase imaging demonstrates a loss of signal in a lipid-rich adenoma, on the out-of phase image compared with the corresponding in-phase imaging. A metastatic deposit does not demonstrate this loss of signal [46] .
MRI should be performed in large tumours prior to surgery to assess vascular invasion [47] .
Signal intensity within adrenocortical carcinomas and pheochromocytomas is significantly higher and heterogeneous on T1-and especially on T2-weighted images, as well as on Diffusion Weighted Imaging [6] . Pheochromocytoma appears as a "light-bulb" bright lesion on T2-weighted image and has almost the same signal intensity as CSF [48] .
If there is suspicion for pheochromocytoma and CT or MRI are not conclusive you may use either I131 MIBG or In111 octreotide [43] .
If there is problem in localization of a pheochromocytoma then 18F-DOPA PET is superior to 123I-MIBG scintigraphy and CT/MRI [49] . STEP 2: (History taking, examining the patient and biochemical tests)
In history taking and clinical examination check for, past history of malignancy, since history of malignancy increases the possibility of adrenal metastasis up to 30-50% [50] , high blood pressureespecially resistant hypertension, abdominal obesity but with thin arms and legs, reddish stretch marks in the abdomen, a "moon" face, weak muscles, acne, and fragile skin that heals poorly, flank pain, elevated heart rate, orthostatic hypotension, palpitations, anxiety often resembling that of a panic attack, ephidrosis ( diaphoresis is a misnomer, the correct is ephidrosis (= Greek for sweating)), pallor, weight loss and evidence of sex hormones hypersecretion.
Proceed with the following tests: a 1 mg overnight dexamethasone (DST) suppression test [5, 30, 41] and plasma metanephrines and urinary fractionated metanephrines [5, 52] .
The rationale for the DST suppression test is to detect autonomous cortisol secretion. If positive, then proceed with confirmatory tests [30] . These are: two days 2mg dexamethasone test, midnight salivary measurement of cortisol (SMC), blood specimen for ACTH, serum and 24-hr urine cortisol [30] . If these are also positive then proceed to surgery after proper preparation.
NEGMAI [5] suggest interpretation of the results of the 1 mg overnight dexamethasone test as a continuous rather than categorical [yes/no] variable and recommend using serum cortisol levels post dexamethasone ≤50 nmol/L [≤1.8 µg/dL] as a diagnostic criterion for the exclusion of autonomous cortisol secretion. They suggest that post-dexamethasone serum cortisol levels between 51 and 138 nmol/L (1.9-5.0 µg/dL) should be considered as evidence of 'possible autonomous cortisol secretion' and cortisol levels post dexamethasone >138 nmol/L (>5.0 µg/dL) should be taken as evidence of 'autonomous cortisol secretion' [5] .
They also recommend that for the clinical management of the patient, comorbidities and the age of the patient is of major importance [5] . Concerning confirmatory tests they use the word "might" despite the fact that in the literature until now it has been recommended to proceed with confirmatory tests [30, 53, 54] .
Check also for fasting hyperglycemia, hypokalemia, hyperlipidemia, and leukocytosis with relative lymphopenia [30] . In case of virilization or feminization, check for sex hormones overproduction.
In patients with a history of hypertension, especially resistant and/or hypokalemia, suspect primary aldosteronism (PA) and proceed to measurement of ARR [55] . The definition of resistant hypertension is, when, despite the fact that we use 3 antihypertensive medications, which belong to different classes, concurrently we cannot achieve blood pressure below or equal with the recommendations [56] . ARR is currently the most reliable available means of screening for PA [55] . If this is positive then proceed with one of the four confirmatory tests. These are: oral sodium loading, saline infusion test, fludrocortisone suppression test, and captopril challenge [55] .
After confirmation of PA proceed with localizing techniques that is adrenal vein sampling (AVS) and/or CT. For cases in which aldosterone producing adenoma (APA) is highly likely (patients ≤40 years of age with marked primary aldosteronism, e.g. PAC ≥30 ng/dL [832 pmol/L]) and a well-defined, hypodense adrenal mass (>1 cm on CT scan) is identified, AVS can be bypassed and the patient can undergo unilateral laparoscopic adrenalectomy [57] [58] [59] .
If plasma metanephrines are more than four times the upper limit the probability of pheochromocytoma is almost 100% [57] . Significant metanephrine elevations imply epinephrine excess, which localizes tumours to the adrenal medulla [58] . Levels of plasma metanephrines greater than 96 pg/mL [59, 60] are considered abnormal.
If the plasma metanephrines level is less than 4 times the upper limit, we proceed with the clonidine suppression test and measurement of serum catecholamines [61] . We can diagnose pheochromocytoma if after three hours of the clonidine suppression test, the levels of metanephrines are not less than 40%. This test has sensitivity 100% and specificity 96% [62, 63] .
The majority of studies suggest that measurement of plasma free metanephrines is a superior test to 24h urinary specimen, for confirming or excluding the diagnosis of pheochromocytoma [52, 57, 64, 65] . Young WF recommends the addition of measurement of fractionated metanephrines and catecholamines in a 24-hr urinary specimen [30] in order to increase the sensitivity by 5% [66] and is especially helpful in diagnosing patients with dopaminesecreting neoplasms [67] .
Radiology does not offer any direct proof of hormone production but may offer an indirect clue if the contralateral adrenal is atrophied [68] .
STEP 3A: (DST positive).
If DST suppression tests and one of the confirmatory tests are positive then after proper preparation proceed to surgery. At least two distinct methods must be abnormal to diagnose Cushing's syndrome.
STEP 3B: (Pheochromocytoma).
If pheochromocytoma is diagnosed, then check for familial pheochromocytoma syndromes that exist with the pheochromocytoma. These are:
1. MEN type 2 is characterized by unilateral or bilateral pheochromocytoma, medullary thyroid carcinoma, hyperplasia and/or neoplasia of various endocrine tissues. MEN2 has an increased risk for parathyroid adenoma or hyperplasia [69] .
2. Von Hippel-Lindau (VHL) syndrome: The diagnosis of VHL is made in individual with renal cell carcinoma, retinal angioma, pheochromocytoma and cerebellar or spinal hemangioblastoma [70] .
3. Type 1 neurofibromatosis (NF1). NF1 is characterized by any combination of two of the following: a first-degree family relative with NF1; neurofibromas; intertriginous freckling; Lisch nodules; optic pathway gliomas; cafe-au-lait spots; and distinctive bony lesions [71] .
4. Medullary thyroid carcinoma. So, in case of pheochromocytoma, screen for thyroid, parathyroids, eyes, kidneys and central nervous system diseases.
Then after proper preparation proceed to surgery.
STEP3C: (Primary aldosteronism).
If ARR is abnormal and a confirmatory test is positive you may proceed with adrenal veins sampling to localize the diseased adrenal. Then if lesion is unilateral, consider surgery and if bilateral start pharmaceutical treatment with a mineralocorticoid receptor antagonist, usually spironolactone.
STEP3D: (Patient with virilization or feminization signs).
NEGMAI suggest measurement of sex hormones and steroid precursors in patients with clinical or imaging features suggestive of adrenocortical carcinoma [5] .
STEP 4: (Follow-up).
If none of the tests is abnormal and the imaging characteristics are not suspicious then, according to NEGMAI, the follow-up of the patient is:
1. In patients with a mass <4 cm with clear benign features on imaging studies, no further imaging follow-up.
2. If a patient with indeterminate adrenal mass is not operated, they suggest a non-contrast CT or MRI after 6-12 months to exclude significant growth. They define significant growth as an enlargement by more than 20% (in addition to at least a 5 mm increase in maximum diameter) during this period. If the enlargement is less than this, they recommend additional imaging after 6-12 months.
3. They do not recommend further hormonal work up, if the initial work-up was normal unless new clinical signs of endocrine activity appear or there is worsening of comorbidities.
4. In patients with "autonomous cortisol secretion" without signs of overt Cushing's syndrome, they suggest annual clinical reassessment for cortisol excess comorbidities potentially related to cortisol excess.
DISCUSSION
CT must be added in all cases that AI was discovered by U/S. Density, imaging characteristics may help in diagnosing AI. In CT, density less than 10 HU indicates, lipid rich adenoma. Pitfall to this may be some cases of pheochromocytoma. Smooth margins and homogeneous density can be seen in both benign and malignant disease. Heterogeneity can be seen in cancer, myelolipoma and adrenal cysts. Myelolipoma has very low density <(-30)-(-100) HU.
Malignant morphologic features are irregular margin and heterogeneous density with a thick enhancing rim, at presenting contrast-enhanced CT. If density is more than 10 HU, then proceed with washout CT. If washout is more than 60% then a diagnosis of an adenoma can be made, if it is less than 50% then there is a non adenoma lesion.
In MRI we use both T1 and T2 weighted sequences. MRI uses intracellular lipids to diagnose adenomas. A benign (lipid-rich) adenoma, in chemical shift MRI, loses its signal on out of phase comparing to its in phase images and to reference organs that contain fat [72] . MRI should be performed in large tumours prior to surgery to assess vascular invasion.
If there is suspicion for pheochromocytoma and CT or MRI are not conclusive you may use either I131 MIBG or In111 octreotide [43] . If there is problem in localization of a pheochromocytoma then 18F-DOPA PET is superior to 123I-MIBG scintigraphy and CT/MRI [49] .
Nevertheless the imaging characteristics always proceed with DST and plasma metanephrines and if the patient has a history of hypertension, especially if it is treatment resistant check for PA and do ARR test. If 1mg dexamethasone or ARR are positive then we proceed with confirmatory tests. If DST and confirmatory tests are positive then after proper preparation proceed with surgery. In case ARR and confirmatory test are positive, if lesion is unilateral then proceed with surgery otherwise administer spironolactone.
For tumours more than 4 cm an adrenalectomy is recommended by the majority of authors [16, 30, 41] . As the size of an AI increases, increase and the risk for cancer and increase the chances for "autonomous cortisol secretion" [73, 74] .
NEGMAI recommend screening patients with "autonomous cortisol secretion'" for asymptomatic vertebral fractures. The panel did not reach consensus on recommending assessment of bone mineral density by dual-energy x-ray absorptiometry [5] . Osteoporosis precedes vertebral fractures, so we believe that it would be reasonable to start from checking bone density at the start up tests.
The NEGMAI recommendations received almost immediately critics. Morelli V., et al. [20] , in a study they published almost immediately after the NEGMAI was published, suggest biochemical and morphological tests for all patients for at least 5 years, even if the mass is <4 cm and with benign imaging characteristics and non functioning. This is in accordance with the guidelines [16, 41] before NEGMAI.
Lopez D., et al. [78] , in their study found that nonfunctioning adrenal tumors [NFAT] had significantly higher risk for incident composite diabetes than those without adrenal tumors and that higher "normal" post-dexamethasone serum cortisol ≤50 nmol/L was associated with bigger nonfunctioning AI and higher incidence of T2D. In a similar study, Papanastasiou L., et al. [79] concluded that after mean follow-up 5.54 ±1.7 years patients with NFAT were at greater risk of deteriorating of metabolic parameters. Salcuni A.F., et al. in patients with monolateral AI and SH, adrenalectomy reduces the risk of vertebral fractures [80] .
Tuna M.M., et al. [81] , studied the incidence of various cardiometabolic risk factors in patients with AI and they concluded that there is increasing evidence that several cardiometabolic risk factors occur with higher prevalence in non-functioning adrenal incidentaloma patients compared to agematched healthy subjects. In their study, hypertension prevalence and carotid intima media thickness were higher in the NFAT group.
Actually these studies prove that it is not only risky if we follow the NEGMAI and stop following up a patient with NFAT but we may have to consider surgery even in cases of NFAT. Ye Y. L., et al. [82] in their study 634 patients with adrenal incidentaloma, they concluded that except of followup, we may consider laparoscopic adrenalectomy for small AI. 192 The NEGMAI define as a limit after 1mg dexamethasone, 1.8 µg/dL for exclusion of "autonomous cortisol secretion" despite the fact that Morelli V., et al. in their study proved that the cut off of 1.5 µg/dL showed the best sensitivity for predicting the cardiovascular events in AI patients [77] , this also is in accordance with the study of Lopez D., et al. [78] .
Fontana D., et al., evaluating the role of ultrasonography [U/S] in the follow-up of adrenal incidentalomas, found that at diagnosis, U/S was not sufficiently reliable in evaluating adrenal mass characteristics. Considering the high correlation between U/S and CT size estimation, in the case of a presumably benign lesion, U/S could be considered a simple, economic, and effective method of follow-up, with CT limited to evaluating masses growing over time (CT remains mandatory at diagnosis) [83] .
Having regard to the above study we agree with Morelli V., et al. [20] , who suggest that for all patients with initially apparent benign adrenal mass, a morphological follow-up is needed for at least 5 years and that after the initial CT in the first 6-12 months after the initial diagnosis, the subsequent follow-up could be performed every 2-3 years by an ultrasound evaluation, with the CT scan being reserved in case of suspected growth at the ultrasound imaging.
We feel that it is somehow risky to follow the NEGMAI and that it is safer to follow the recommendations of the American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons (AACE, AAES) [16] or the NIH [41] . AACE and AAES recommendations on follow-up of patients with AI are: 1) AI less than 4 cm and imaging characteristics relevant with benign adrenal adenoma should have CT scan after 3 to 6 months and then after every year for five years.
2) Biochemical tests for hormone evaluation should be done annually for five years.
3) The risk of an AI to increase in size is from 6% to 29% on the fifth year.
4) The risk of an AI to become hormonally active is from 17% to 47% on the fifth year.
5) If a tumor increases in size or becomes hormonally active surgery should be considered.
6) In patients with pheochromocytoma follow-up should be done for the rest of the life as 10-15% recur.
Questions that should be addressed in future research:
1. If after long term (more than 5 years) AI may become malignant.
2. If we have to perform impaired glucose tolerance, test at the initial test and/or in the follow-up.
3. If we have to perform bone density test at the initial tests.
4. If we have to consider surgery at an earlier stage.
5. After how long it is safe to stop following-up patients with AI.
6. If U/S is safe as a follow-up modality. 7. If it is prudent to perform ARR test at the initial biochemical tests, given the fact that primary aldosteronism is the most frequent cause of secondary hypertension and its prevalence is increasing [84] .
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Obiective. Prezentarea unei abordări pas cu pas pentru diagnosticul incidentalomului adrenal (AI).
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